Evidence map›Paper›PMID 41697901›Full record

ArticleChannels (Austin, Tex.)2026

Cholesterol inhibits capsaicin activation of the TRPV1 channel.

Tal Brandwine-Shemmer, Nicolas A Barbera, Irena Levitan, Baruch Minke

Abstract read
In one paragraph

Article in Channels (Austin, Tex.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tal Brandwine-ShemmerDepartment of Medical Neurobiology Faculty of Medicine and Edmond and Lily Safra Center for Brain Sciences (ELSC), The Hebrew University, Jerusalem, Israel.
Nicolas A BarberaDivision of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Irena LevitanDivision of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Baruch MinkeDepartment of Medical Neurobiology Faculty of Medicine and Edmond and Lily Safra Center for Brain Sciences (ELSC), The Hebrew University, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TRPV1 is a polymodal ion channel activated by vanilloids, noxious heat, and pro-inflammatory signals. A recent cryo-EM structure of human TRPV1 bound to SAF312, a potent, selective, noncompetitive antagonist, revealed a cholesterol molecule occupying the vanilloid-binding pocket, a site well established as the activation locus for vanilloid agonists. This observation led us to test whether cholesterol functionally inhibits capsaicin-dependent TRPV1 activation. Using HEK293 cells heterologously expressing TRPV1, we found that membrane cholesterol enrichment markedly suppressed capsaicin-evoked currents at low agonist concentrations, whereas responses to saturating capsaicin were unaffected. The functional interaction between cholesterol and capsaicin was further supported by site-directed mutagenesis targeting the conserved Gly563, a residue within the S4-S5 linker of the vanilloid-binding pocket. The G563S mutation reduced the sensitivity to capsaicin and caused slow and incomplete deactivation; nevertheless, elevated cholesterol further suppressed capsaicin-evoked activity. Together, these findings support a model in which cholesterol competes with capsaicin at the vanilloid-binding pocket to inhibit activation of the TRPV1 channel.

Indexed as

CapsaicinCholesterolTRPV Cation ChannelsBinding SitesHEK293 CellsHumansCapsaicinCholesterolTRPV1 protein, humanTRPV Cation Channelscapsaicincholesteroldocking analysisGly563Ser TRPV1 mutationmethyl-β-cyclodextrin (MβCD)TRPV1 channel

Identifiers

PMID41697901
PMCPMC12915799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.